Stockreport

Ocugen: Why I Don't Read Too Much Into The Selloff On Phase 2 GA Data [Seeking Alpha]

Ocugen, Inc.  (OCGN) 
PDF OCGN's OCU410 Phase 2 data showed 46% lesion growth reduction in GA, but dose-response inconsistencies and small sample sizes temper enthusiasm. Key catalysts in 2026 [Read more]